- Home
- THAR vs NUWE Comparison
THAR vs NUWE Comparison
Compare THAR & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- NUWE
- Stock Information
- Founded
- THAR 2017
- NUWE 1999
- Country
- THAR United States
- NUWE United States
- Employees
- THAR N/A
- NUWE N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- THAR Health Care
- NUWE Health Care
- Exchange
- THAR Nasdaq
- NUWE Nasdaq
- Market Cap
- THAR 3.3M
- NUWE 3.9M
- IPO Year
- THAR 2022
- NUWE N/A
- Fundamental
- Price
- THAR $1.51
- NUWE $0.40
- Analyst Decision
- THAR Strong Buy
- NUWE Strong Buy
- Analyst Count
- THAR 1
- NUWE 1
- Target Price
- THAR $17.00
- NUWE $17.00
- AVG Volume (30 Days)
- THAR 26.3K
- NUWE 187.8K
- Earning Date
- THAR 05-12-2025
- NUWE 05-13-2025
- Dividend Yield
- THAR N/A
- NUWE N/A
- EPS Growth
- THAR N/A
- NUWE N/A
- EPS
- THAR N/A
- NUWE N/A
- Revenue
- THAR N/A
- NUWE $8,787,000.00
- Revenue This Year
- THAR N/A
- NUWE $26.81
- Revenue Next Year
- THAR N/A
- NUWE $48.74
- P/E Ratio
- THAR N/A
- NUWE N/A
- Revenue Growth
- THAR N/A
- NUWE N/A
- 52 Week Low
- THAR $0.95
- NUWE $0.40
- 52 Week High
- THAR $6.39
- NUWE $8.40
- Technical
- Relative Strength Index (RSI)
- THAR 54.61
- NUWE 15.96
- Support Level
- THAR $1.41
- NUWE $0.76
- Resistance Level
- THAR $1.64
- NUWE $0.95
- Average True Range (ATR)
- THAR 0.11
- NUWE 0.09
- MACD
- THAR 0.01
- NUWE -0.05
- Stochastic Oscillator
- THAR 63.86
- NUWE 0.00
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.